> Detailanzeige

Zhang, Xin; Liu, Yi; Dai, Lei; Shi, Gang; Deng, Jie; Luo, Qiang; Xie, Qian; Cheng, Lin; Li, Chunlei; Lin, Yi; Wang, Qingnan; Fan, Ping; Zhang, Hantao; Su, Xiaolan; Zhang, Shuang; Yang, Yang; Hu, Xun; Gong, Qiyong; Yu, Dechao; Zheng, Lei; Deng, Hongxin

BATF2 prevents glioblastoma multiforme progression by inhibiting recruitment of myeloid-derived suppressor cells

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: BATF2 prevents glioblastoma multiforme progression by inhibiting recruitment of myeloid-derived suppressor cells
  • Beteiligte: Zhang, Xin; Liu, Yi; Dai, Lei; Shi, Gang; Deng, Jie; Luo, Qiang; Xie, Qian; Cheng, Lin; Li, Chunlei; Lin, Yi; Wang, Qingnan; Fan, Ping; Zhang, Hantao; Su, Xiaolan; Zhang, Shuang; Yang, Yang; Hu, Xun; Gong, Qiyong; Yu, Dechao; Zheng, Lei; Deng, Hongxin
  • Erschienen: Springer Science and Business Media LLC, 2021
  • Erschienen in: Oncogene
  • Sprache: Englisch
  • DOI: 10.1038/s41388-020-01627-y
  • ISSN: 1476-5594; 0950-9232
  • Schlagwörter: Cancer Research ; Genetics ; Molecular Biology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:p>The basic leucine zipper ATF-like transcription factor 2 (BATF2) has been implicated in inflammatory responses and anti-tumour effects. Little, however, is known regarding its extracellular role in maintaining a non-supportive cancer microenvironment. Here, we show that BATF2 inhibits glioma growth and myeloid-derived suppressor cells (MDSCs) recruitment. Interestingly, extracellular vesicles (EVs) from BATF2-overexpressing glioma cell lines (BATF2-EVs) inhibited MDSCs chemotaxis in vitro. Moreover, BATF2 inhibited intracellular SDF-1α and contributes to decreased SDF-1α in EVs. In addition, BATF2 downregulation-induced MDSCs recruitment were reversed by blocking SDF-1α/CXCR4 signalling upon AMD3100 treatment. Specifically, detection of EVs in 24 pairs of gliomas and healthy donors at different stages revealed that the abundance of BATF2-positive EVs in plasma (BATF2<jats:sup>+</jats:sup>plEVs) can distinguish stage III–IV glioma from stage I–II glioma and healthy donors. Taken together, our study identified novel regulatory functions of BATF2 in regulating MDSCs recruitment, providing a prognostic value in terms of the number of BATF2<jats:sup>+</jats:sup>plEVs in glioma stage.</jats:p>